[go: up one dir, main page]

WO2001073032A3 - Compositions et methodes de therapie et de diagnostic du cancer de la prostate - Google Patents

Compositions et methodes de therapie et de diagnostic du cancer de la prostate Download PDF

Info

Publication number
WO2001073032A3
WO2001073032A3 PCT/US2001/009919 US0109919W WO0173032A3 WO 2001073032 A3 WO2001073032 A3 WO 2001073032A3 US 0109919 W US0109919 W US 0109919W WO 0173032 A3 WO0173032 A3 WO 0173032A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
prostate cancer
therapy
methods
Prior art date
Application number
PCT/US2001/009919
Other languages
English (en)
Other versions
WO2001073032A2 (fr
Inventor
Jiangchun Xu
Davin C Dillon
Jennifer L Mitcham
Susan L Harlocker
Yuqiu Jiang
Michael D Kalos
Gary Richard Fanger
Marc W Retter
John A Stolk
Craig H Day
Thomas S Vedvick
Darrick Carter
Samuel X Li
Aijun Wang
Yasir A W Skeiky
William T Hepler
Robert A Henderson
Original Assignee
Corixa Corp
Jiangchun Xu
Davin C Dillon
Jennifer L Mitcham
Susan L Harlocker
Yuqiu Jiang
Michael D Kalos
Gary Richard Fanger
Marc W Retter
John A Stolk
Craig H Day
Thomas S Vedvick
Darrick Carter
Samuel X Li
Aijun Wang
Yasir A W Skeiky
William T Hepler
Robert A Henderson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/570,737 external-priority patent/US7202342B1/en
Priority claimed from US09/593,793 external-priority patent/US7517952B1/en
Priority claimed from US09/636,215 external-priority patent/US6620922B1/en
Priority claimed from US09/651,236 external-priority patent/US6818751B1/en
Priority claimed from US09/657,279 external-priority patent/US6894146B1/en
Priority claimed from US09/679,426 external-priority patent/US6759515B1/en
Priority claimed from US09/685,166 external-priority patent/US6630305B1/en
Priority to EP01922786A priority Critical patent/EP1311673A2/fr
Priority to AU2001249549A priority patent/AU2001249549A1/en
Application filed by Corixa Corp, Jiangchun Xu, Davin C Dillon, Jennifer L Mitcham, Susan L Harlocker, Yuqiu Jiang, Michael D Kalos, Gary Richard Fanger, Marc W Retter, John A Stolk, Craig H Day, Thomas S Vedvick, Darrick Carter, Samuel X Li, Aijun Wang, Yasir A W Skeiky, William T Hepler, Robert A Henderson filed Critical Corixa Corp
Priority to JP2001570749A priority patent/JP2004504808A/ja
Priority to CA002403909A priority patent/CA2403909A1/fr
Publication of WO2001073032A2 publication Critical patent/WO2001073032A2/fr
Publication of WO2001073032A3 publication Critical patent/WO2001073032A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des méthodes de thérapie et de diagnostic du cancer, en particulier du cancer de la prostate. Des compositions servant d'illustration contiennent un ou plusieurs polypeptides spécifiques à la prostate, des portions immunogènes de ceux-ci, des polynucléotides codant ces polypeptides, une cellule de présentation d'antigène exprimant ces polypeptides, ainsi que des lymphocytes T spécifiques à des cellules exprimant ces polypeptides. Les compositions décrites sont utiles, par exemple, dans le diagnostic, la prévention et/ou le traitement de maladies, en particulier du cancer de la prostate.
PCT/US2001/009919 2000-03-27 2001-03-27 Compositions et methodes de therapie et de diagnostic du cancer de la prostate WO2001073032A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002403909A CA2403909A1 (fr) 2000-03-27 2001-03-27 Compositions et methodes de therapie et de diagnostic du cancer de la prostate
JP2001570749A JP2004504808A (ja) 2000-03-27 2001-03-27 前立腺癌の治療及び診断のための組成物及び方法
EP01922786A EP1311673A2 (fr) 2000-03-27 2001-03-27 Compositions et methodes de therapie et de diagnostic du cancer de la prostate
AU2001249549A AU2001249549A1 (en) 2000-03-27 2001-03-27 Compositions and methods for the therapy and diagnosis of prostate cancer

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US53685700A 2000-03-27 2000-03-27
US09/536,857 2000-03-27
US56810000A 2000-05-09 2000-05-09
US09/568,100 2000-05-09
US09/570,737 US7202342B1 (en) 1999-11-12 2000-05-12 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/570,737 2000-05-12
US09/593,793 2000-06-13
US09/593,793 US7517952B1 (en) 1997-02-25 2000-06-13 Compositions and methods for the therapy and diagnosis of prostate cancer
US60578300A 2000-06-27 2000-06-27
US09/605,783 2000-06-27
US09/636,215 US6620922B1 (en) 1997-02-25 2000-08-09 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/636,215 2000-08-10
US09/651,236 2000-08-29
US09/651,236 US6818751B1 (en) 1997-08-01 2000-08-29 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/657,279 US6894146B1 (en) 1997-02-25 2000-09-06 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/657,279 2000-09-06
US09/679,426 2000-10-02
US09/679,426 US6759515B1 (en) 1997-02-25 2000-10-02 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/685,166 US6630305B1 (en) 1999-11-12 2000-10-10 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/685,166 2000-10-10
US70972900A 2000-11-09 2000-11-09
US09/709,729 2000-11-09

Publications (2)

Publication Number Publication Date
WO2001073032A2 WO2001073032A2 (fr) 2001-10-04
WO2001073032A3 true WO2001073032A3 (fr) 2003-03-13

Family

ID=27582800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009919 WO2001073032A2 (fr) 2000-03-27 2001-03-27 Compositions et methodes de therapie et de diagnostic du cancer de la prostate

Country Status (5)

Country Link
EP (1) EP1311673A2 (fr)
JP (1) JP2004504808A (fr)
AU (1) AU2001249549A1 (fr)
CA (1) CA2403909A1 (fr)
WO (1) WO2001073032A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227008B2 (en) 1999-04-12 2007-06-05 Agensys, Inc. 13-transmembrane protein expressed in prostate cancer
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US9096907B2 (en) 2004-12-24 2015-08-04 Stichting Katholieke Universiteit, The University Medical Centre Nijmegen Prostate cancer prognostic compositions and kits
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ES2324503T3 (es) 1997-04-10 2009-08-07 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, genes pca3 y metodos de uso.
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
CA2328989C (fr) 1998-06-01 2012-02-07 Urogenesys, Inc. Nouveaux antigenes transmembranaires du type serpentin exprimes dans des cancers humains et utilisation de ces antigenes
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
WO2001023550A2 (fr) 1999-09-29 2001-04-05 Diagnocure Inc. Variantes l'arnm du pca3 dans les tissus benins et malins de la prostate
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US7208280B2 (en) 1999-10-05 2007-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
PT1517913E (pt) * 1999-10-07 2007-05-31 Corixa Corp Sequência codificante de mycobacterium turberculosis para expressão de proteínas heterólogas.
DE60139963D1 (de) 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
AU2002227365A1 (en) 2000-12-07 2002-06-18 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
EP1988097A1 (fr) * 2001-05-09 2008-11-05 Corixa Corporation Compositions et procédés pour le traitement et le diagnostic du cancer de la prostate
EP1539805A4 (fr) * 2001-05-15 2005-11-16 Agensys Inc Acides nucleiques et proteines correspondantes dits 101p3a11 ou phor-1 servant au traitement et a la detection de cancers
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7332290B2 (en) 2001-08-02 2008-02-19 The Regents Of The University Of Michigan Dectection of AMACR cancer markers in urine
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
EP1429793B1 (fr) 2001-09-06 2015-02-25 Agensys, Inc. Acide nucleique et proteine correspondante designes par steap-1 utiles dans le traitement et la detection du cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2003210663A1 (en) 2002-01-25 2003-09-02 The Regents Of The University Of California Methods of modulating cold sensory perception
ES2285174T3 (es) * 2002-06-11 2007-11-16 Glaxosmithkline Biologicals S.A. Composiciones inmunogenicas.
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
ES2427853T3 (es) 2003-02-07 2013-11-04 Diagnocure Inc. Procedimiento para detectar cáncer de próstata en una muestra
CA2612168A1 (fr) * 2005-06-14 2006-12-21 Dnavec Corporation Methodes de preparation d'anticorps
CA2623775A1 (fr) 2005-09-19 2007-03-29 Veridex, Llc Methodes et materiaux d'identification de l'origine d'un carcinome d'origine primaire inconnue
US7622573B2 (en) * 2006-01-17 2009-11-24 Biolex, Inc. Expression control elements from the lemnaceae family
WO2007100568A2 (fr) * 2006-02-24 2007-09-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Récepteurs de lymphocytes t, matériaux associés et procédés d'utilisation
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
PL2845866T3 (pl) 2006-10-27 2017-10-31 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowanie
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
EP4584297A1 (fr) * 2022-09-11 2025-07-16 Yeda Research and Development Co. Ltd Anticorps anti-klk4 et leurs utilisations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037039A1 (fr) * 1997-02-19 1998-08-27 Asahi Kasei Kogyo Kabushiki Kaisha Fertilisant granulaire enrobe d'une pellicule de protection decomposable et son procede de production
WO1998037418A2 (fr) * 1997-02-25 1998-08-27 Corixa Corporation Composes servant au diagnostic immunologique de cancer de la prostate et leurs procedes d'utilisation
WO2000004149A2 (fr) * 1998-07-14 2000-01-27 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001025272A2 (fr) * 1999-10-04 2001-04-12 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001034802A2 (fr) * 1999-11-12 2001-05-17 Corixa Corporation Compositions et methodes de traitement et de diagnostic du cancer de la prostate
WO2001051633A2 (fr) * 2000-01-14 2001-07-19 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1988097A1 (fr) * 2001-05-09 2008-11-05 Corixa Corporation Compositions et procédés pour le traitement et le diagnostic du cancer de la prostate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037039A1 (fr) * 1997-02-19 1998-08-27 Asahi Kasei Kogyo Kabushiki Kaisha Fertilisant granulaire enrobe d'une pellicule de protection decomposable et son procede de production
WO1998037418A2 (fr) * 1997-02-25 1998-08-27 Corixa Corporation Composes servant au diagnostic immunologique de cancer de la prostate et leurs procedes d'utilisation
WO2000004149A2 (fr) * 1998-07-14 2000-01-27 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001025272A2 (fr) * 1999-10-04 2001-04-12 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001034802A2 (fr) * 1999-11-12 2001-05-17 Corixa Corporation Compositions et methodes de traitement et de diagnostic du cancer de la prostate
WO2001051633A2 (fr) * 2000-01-14 2001-07-19 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227008B2 (en) 1999-04-12 2007-06-05 Agensys, Inc. 13-transmembrane protein expressed in prostate cancer
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US7641905B2 (en) 2001-04-10 2010-01-05 Agensys, Inc. Methods of inducing an immune response
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US10597463B2 (en) 2004-04-22 2020-03-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11401347B2 (en) 2004-04-22 2022-08-02 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US9096907B2 (en) 2004-12-24 2015-08-04 Stichting Katholieke Universiteit, The University Medical Centre Nijmegen Prostate cancer prognostic compositions and kits
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US11685790B2 (en) 2017-04-03 2023-06-27 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US12129306B2 (en) 2017-04-03 2024-10-29 Hoffman-La Roche Inc. Antibodies binding to STEAP-1

Also Published As

Publication number Publication date
JP2004504808A (ja) 2004-02-19
EP1311673A2 (fr) 2003-05-21
AU2001249549A1 (en) 2001-10-08
CA2403909A1 (fr) 2001-10-04
WO2001073032A2 (fr) 2001-10-04

Similar Documents

Publication Publication Date Title
WO2001051633A3 (fr) Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
WO2001073032A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2002089747A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
WO2004052276A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
WO2001092581A8 (fr) Compositions et methodes permettant le traitement et le diagnostic du cancer de l'ovaire
WO2002060317A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du pancreas
WO2001072295A3 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
WO2002074156A3 (fr) Compositions et procedes de therapie et de diagnostic du cancer du colon
WO2002014503A3 (fr) Compositions et methodes de traitement et de diagnostic de cancers associes a her-2/neu
WO2002004514A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
WO2002074237A8 (fr) Compositions et procedes de therapie et de diagnostic du cancer du rein
WO2002092001A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
WO2002012328A8 (fr) Compositions et methodes utilisees dans la therapie et le diagnostic du cancer du colon
WO2002016413A8 (fr) Vaccins
WO2002058534A8 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du colon
WO2003037267A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer des poumons
WO2002078516A3 (fr) Compositions et methodes de traitement et de diagnostic de cancers
WO2001077168A3 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon
WO2003013431A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du sein
WO2002012280A3 (fr) Compositions et procedes pour le diagnostic et le traitement du cancer du colon
WO2002039885A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2001090152A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du sein
WO2005051990A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du sein
WO2002000174A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
WO2003086175A8 (fr) Compositions et procedes destines au traitement et au diagnostic du cancer du poumon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2403909

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 570749

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001922786

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001922786

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)